Image

Effect of Adapted Physical Activity on Sleep Quality in People with Alcohol Use Disorder

Effect of Adapted Physical Activity on Sleep Quality in People with Alcohol Use Disorder

Recruiting
18-65 years
All
Phase N/A

Powered by AI

Overview

This feasibility study aims to assess interest, recruitment, and adherence to a supervised physical activity (APA) program among individuals with Alcohol Use Disorder (AUD). It also investigates the program's impact on sleep quality and efficiency. Key objectives include evaluating recruitment feasibility, assessing randomization acceptance, quantifying adherence rates, and identifying sensitive sleep assessment tools. The study will explore whether APA improves sleep outcomes in AUD patients with sleep complaints, laying groundwork for larger-scale research.

Participants will engage in APA sessions, complete sleep assessments (including sleep diaries and psychometric scales), and provide sociodemographic data and past activity adherence.

Eligibility

Inclusion Criteria:

  • Subjects aged 18 to 65 years inclusive
  • Present an Alcohol Use Disorder (AUD) with at least 2 positive items as defined by the DSM-5
  • Present a sleep complaint with a score on the Pittsburgh Sleep Quality Index (PSQI) ≥ 5
  • Present active alcohol consumption with at least 6 days of excessive alcohol consumption in the last 4 weeks
  • Speak and understand French
  • Live within 30 minutes of the University Hospital of Besançon
  • Treatment allowed if stabilized for at least 4 weeks
  • Signature of informed consent indicating that the subject has understood the purpose and procedures required by the study and agrees to participate and comply with the requirements and restrictions inherent to the study
  • Signed automobile safety contract:
    1. The participant agrees to hand over the keys to their vehicle if necessary.
    2. The keys will be returned when the blood alcohol level is below 0.25 mg/L
    3. The participant agrees to name one or more people to contact in case the medical staff deems the participant unfit to return home alone.
  • Affiliation to a French social security system or beneficiary of such a system
  • Postmenopausal women for at least 24 months, surgically sterilized, or, for women of childbearing age, using an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches) (self-reported)

Exclusion Criteria:

  • Decompensated heart failure
  • Complex ventricular arrhythmias
  • Severe uncontrolled hypertension
  • Pulmonary hypertension (>60 mmHg)
  • Myocarditis or acute pericardial effusion
  • Severe obstructive cardiomyopathy
  • Severe and/or symptomatic aortic stenosis
  • All acute illnesses
  • All decompensated or unstable chronic conditions
  • Significant malnutrition
  • Extreme fatigue and/or manifest physical incapacity
  • Severe anemia
  • Severe intoxication (psychoactive substances)
  • Severe withdrawal syndrome (Cushman >7)
  • Relative contraindications for high-intensity physical activities:
  • Chronic respiratory insufficiency on long-term oxygen
  • Severe chronic respiratory conditions
  • Complicated diabetes with severe retinopathy
  • Sickle cell disease
  • Mild intoxication (psychoactive substances)
  • Mild withdrawal syndrome (Cushman >2)
  • Musculoskeletal and dermatological limitations: Unhealed traumatic injuries.
  • Musculoskeletal and dermatological limitations: Osteoarticular conditions in acute flare (osteoarthritis, arthritis).
  • Musculoskeletal and dermatological limitations: Diabetes with plantar ulcer.
  • Musculoskeletal and dermatological limitations: Pressure ulcers and evolving or chronic wounds.
  • On the day of signing consent: Blood alcohol concentration > 0 mg/L of expired air.
  • On the day of signing consent: If blood alcohol concentration is < 0.25 mg/L, the participant may join other therapeutic activities and return home autonomously.
  • On the day of signing consent: If blood alcohol concentration is > 0.25 mg/L without clinical signs of intoxication, the participant may join other therapeutic activities and return home accompanied.
  • On the day of signing consent: If blood alcohol concentration is > 0.25 mg/L with clinical signs of intoxication, the participant will not join other therapeutic activities. A supervised room placement will be offered, and emergency services may be contacted if intoxication is unusually high (>2 g/L).
  • Excessive alcohol consumption ≥ 6 days in the 4 weeks prior to inclusion.
  • Average alcohol consumption > 20 g/day or > 100 g/week.
  • CIWA score ≥ 9, indicating the need for medication-assisted withdrawal.
  • High physical activity levels according to the Global Physical Activity Questionnaire (GPAQ).
  • Concurrent treatment with disulfiram, acamprosate, benzodiazepines, topiramate, baclofen, naltrexone, nalmefene, melatonin, and beta-blockers.
  • Unstable or recently changed treatments (<4 weeks).
  • History of pre-delirium tremens or delirium tremens.
  • Substance use disorder (other than alcohol/nicotine per DSM-5).
  • Severe chronic psychiatric disorders (e.g., schizophrenia, paranoia, bipolar types I/II).
  • Acute psychiatric disorders requiring immediate hospitalization or adjustment of psychotropic medications.
  • Advanced somatic disorders contraindicating physical activity.
  • Lack of signed automobile safety contract.
  • Legal incapacity or refusal to sign consent.
  • No health insurance.
  • Anticipated poor cooperation or difficulty completing the study
  • Pregnant or breastfeeding women.
  • Currently in the exclusion period of another study or listed in the national volunteer registry.

Study details
    Alcohol Use Disorder

NCT06706349

Centre Hospitalier Universitaire de Besancon

23 August 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.